Critical Drug Interactions with Azathioprine (Imuran)
The most dangerous interaction with azathioprine is allopurinol (or febuxostat), which requires an immediate dose reduction of azathioprine to 25-33% of the usual dose to prevent severe, life-threatening myelotoxicity 1, 2.
Life-Threatening Interactions Requiring Dose Adjustment
Allopurinol and Febuxostat
- Mechanism: Allopurinol inhibits xanthine oxidase, one of azathioprine's primary inactivation pathways, leading to accumulation of toxic metabolites 2
- Action required: Reduce azathioprine dose to approximately 1/3 to 1/4 of usual dose when co-prescribed 2
- Additional caution: Patients with low/absent TPMT activity receiving both drugs need further dose reduction or alternative therapy, as both metabolic pathways (TPMT and xanthine oxidase) are affected 2
- Note: While traditionally contraindicated, controlled co-prescription at reduced doses may improve efficacy in non-responders, though this remains experimental in dermatology 1
Ribavirin
- Risk: Severe pancytopenia reported when combined with azathioprine 2
- Mechanism: Ribavirin inhibits inosine monophosphate dehydrogenase (IMDH), causing accumulation of the toxic metabolite 6-MTITP 2
- Monitoring: Weekly CBC for first month, twice monthly for months 2-3, then monthly 2
High-Risk Interactions Requiring Enhanced Monitoring
Warfarin and Other Coumarins
- Effect: Azathioprine causes warfarin resistance, requiring 2.5-fold or greater increase in warfarin dose 1, 3
- Onset: Rapid (within days) 1
- Action: Close INR monitoring and expect substantial warfarin dose increases 1, 2
- Evidence: Multiple case reports document this interaction, including acenocoumarol 4, 3
Other Immunosuppressants
- Drugs: Cyclophosphamide, methotrexate, ciclosporin, anti-TNF agents, other biologics 1
- Risk: Increased myelotoxicity 1
- Action: More frequent CBC monitoring required 1
Myelotoxic Drugs
- Examples: Co-trimoxazole, trimethoprim, clozapine 1
- Risk: Exaggerated leukopenia, especially in transplant recipients 1, 2
- Action: Exercise caution and increase monitoring frequency 1
ACE Inhibitors
- Risk: Anemia and severe leukopenia reported 2
- Action: Monitor CBC closely when initiating ACE inhibitors in patients on azathioprine 2
Moderate-Risk Interactions
Aminosalicylates (Sulfasalazine, Mesalazine, Olsalazine)
- Mechanism: In vitro evidence shows TPMT enzyme inhibition 2
- Clinical significance: In vivo study showed modest decrease in 6-thioguanine nucleotide levels after aminosalicylate withdrawal, though mechanism unclear 5
- Action: Use with caution and increase FBC monitoring 1
- Context: Often co-prescribed in inflammatory bowel disease 1
Contraindicated Combinations
Live Vaccines
- Absolute contraindication: Should not be given to immunocompromised patients on azathioprine 1
Monitoring Requirements for All Interactions
Standard monitoring 2:
- Weekly CBC (including platelets) for first month
- Twice monthly for months 2-3
- Monthly thereafter or more frequently with dose changes
Enhanced monitoring when high-risk drugs added:
- Consider weekly CBC when initiating myelotoxic agents
- Weekly INR monitoring when adjusting warfarin doses
Common Pitfalls to Avoid
- Failing to reduce azathioprine dose with allopurinol: This is the most dangerous oversight and can be fatal
- Assuming TPMT testing eliminates need for CBC monitoring: TPMT testing cannot substitute for regular blood count monitoring 2
- Overlooking warfarin resistance: Expect dramatic increases in warfarin requirements, not minor adjustments
- Inadequate monitoring in elderly: Polypharmacy increases interaction risk; elderly require closer monitoring 1
Interactions with Weak or No Clinical Evidence
The following interactions are listed in some sources but lack strong clinical evidence 1:
- Succinylcholine and tubocurarine (based only on animal studies with supratherapeutic doses)
- Furosemide
- Bendroflumethiazide
- NSAIDs
These do not require specific precautions beyond standard monitoring.